Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Parenteral Nutrition · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Parenteral Nutrition | DRUG | - |
Inclusion Criteria: * Documentation of informed consent * Inborn * Gestational age between 23 weeks and 0/7 days and 29 weeks and 6/7 days * If subject is transferred to another hospital, the ability to obtain follow-up data on outcomes * No major anomalies * Ability to begin parenteral nutrition w...
Parenteral Nutrition is used for malnutrition, specifically in premature neonates who require intravenous feeding. It is a small molecule metabolic therapy being developed by Pediatrix Medical Group, Inc. The treatment involves delivering amino acids and other nutrients directly into the bloodstream to support growth in infants who cannot eat normally.
Parenteral Nutrition is being developed by Pediatrix Medical Group, Inc., a company traded under the ticker MD. The company is conducting clinical research on this therapy for malnutrition in premature neonates, with the goal of improving growth outcomes through intravenous amino acid administration.
Parenteral Nutrition is in Phase 3 clinical development. It is an investigational therapy, not yet approved by regulatory authorities. The Phase 3 trial has been completed, evaluating the safety and efficacy of different amino acid doses on growth in premature neonates with malnutrition.
Parenteral Nutrition has one completed Phase 3 clinical trial, registered as NCT00120926, titled 'Dose Comparison of Amino Acids on Growth in Premature Neonates.' This randomized, double-blind study enrolled 150 participants in the United States and assessed growth outcomes in premature neonates with malnutrition.
The Phase 3 clinical trial for Parenteral Nutrition, NCT00120926, was randomized and double-blind, but it was uncontrolled, meaning there was no comparator group. The study enrolled 150 premature neonates with malnutrition and was conducted in the United States, with results now completed.